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Radiotherapy for squamous cell carcinoma of the oropharynx:
long term results and multivariate analysis of prognostic factors
Zbigniew Szutkowski, Andrzej Kawecki, Andrzej Hliniak, El˝bieta Kraszewska
I n t r o d u c t i o n.  The aim of the study was to analyse the results of treatment and prognostic factors related to clinical and
therapeutic characteristics in patients with oropharyngeal cancer.
M e t h o d s.  241 patients with proven oropharyngeal cancer were irradiated with radical intent at the Maria Sklodowska-Curie
Memorial Cancer Centre and Institute of Oncology in Warsaw between 1984 and 1995. The total dose ranged between 66 and
72Gy delivered in 2Gy fractions 5-times weekly. The majority of patients presented as advanced cases T3, T4 – 152 patients
(63%) and N2, N3 – 89 patients (37%).
Curves of overall survival and local, regional control were estimated using the Kaplan-Meier method. Analysis of the
prognostic factors was performed using Cox's multivariate proportional risk model.
R e s u l t s.  5-year overall survival probability was 25%. 5-year local regional control probability in patients with complete
regression after radiotherapy was 55%. WHO-2 performance status had a significantly negative influence on overall survival,
as compared to WHO-0 (p=0.02). T4 stage reduced overall survival probability, as compared with others stages (p=0.04). The
analysis has also shown unfavourable influence of the clinical stage N2c on overall survival. Patients with stage N2c had
a three-fold higher risk of death, as compared to others (p=0.002). Hemoglobin level higher than 13g/dL reduced the risk of
death, as compared to patients with hemoglobin level equal or lower than 13g/dL (0.0002). Patients with breaks during
irradiation (prolonged overall treatment time) had worse prognosis, as compared to patients without breaks. This relationship
was marginally significant (p=0.06). Loco-regional control analysis showed that only the hemoglobin level was significant. In
patients with hemoglobin level over 13g/dL the risk of recurrence was lower than in patients with hemoglobin equal or lower
than 13g/dL (p=0.013).
C o n c l u s i o n.  Performance status, advanced T and N stage, hemoglobin concentration and breaks during the treatment
influence the overall survival of patients with oropharyngeal cancer undergoing radical radiotherapy. The level of hemoglobin
was found to be the only factor influencing loco-regional control.
Radioterapia raka p∏askonab∏onkowego ustnej cz´Êci gard∏a
– wyniki odleg∏e i analiza czynników prognostycznych
C e l.  Celem pracy jest ocena wp∏ywu wybranych czynników klinicznych na wyniki radioterapii stosowanej jako wy∏àczne lecze-
nie chorych na raka ustnej cz´Êci gard∏a.
M a t e r i a ∏  i m e t o d a .   Analizie poddano 241 chorych na raka ustnej cz´Êci gard∏a, leczonych napromienianiem z za∏o-
˝eniem radykalnym w Centrum Onkologii w Warszawie w latach 1984-1995. U 152 chorych (63%) stwierdzono zaawanso-
wanie miejscowe T3-4, a u 89 chorych (37%) przerzuty do w´z∏ów ch∏onnych szyi o zaawansowaniu N2-3. U wszystkich cho-
rych przeprowadzono radioterapi´ z za∏o˝eniem radykalnym (frakcjonowanie konwencjonalne, za∏o˝ona dawka ca∏kowita 66-
-72 Gy). Krzywe prze˝ycia ca∏kowitego i prze˝ycia bez nawrotu miejscowego i regionalnego estymowano przy u˝yciu metody
Kaplana-Meiera. Wp∏yw czynników klinicznych na czas prze˝ycia i czas bez nawrotu miejscowego i regionalnego oceniono za
pomocà wielowariantowego modelu proporcjonalnego ryzyka Coxa.
W y n i k i.  5-letnie prze˝ycie ca∏kowite wynios∏o 25%. 5-letnie prze˝ycie bez nawrotu loko regionalnego u chorych, u których
uzyskano ca∏kowità regresj´ nowotworu, wynios∏o 55%. Analiza statystyczna dotyczàca czasu prze˝ycia ca∏kowitego wykaza-
∏a, ˝e chorzy ze stopniem sprawnoÊci WHO-2 mieli znamiennie gorsze rokowanie w porównaniu z chorymi ze stopniem
WHO-0 (p=0,02). Zaawansowanie miejscowe raka T4 wiàza∏o si´ ze skróceniem czasu prze˝ycia ca∏kowitego chorych
w porównaniu do pozosta∏ych, o mniejszym zaawansowaniu (p=0,04). Stwierdzono wyjàtkowo niekorzystny wp∏yw na prze-
˝ycie ca∏kowite obustronnego lub przeciwleg∏ego do guza pierwotnego zaj´cia w´z∏ów ch∏onnych, wykazujàc 3-krotnie wi´k-
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Introduction
Oropharyngeal cancer is a relatively frequent malignancy
of the head and neck. In 1999 more than 700 new cases of
the oropharyngeal cancer were diagnosed in Poland [1].
The most frequent pathological type of oropharyngeal
cancer is squamous cell carcinoma. Other pathological
types are very rare in this localization.
Squamous cell carcinoma of the oropharynx may,
potentially, be treated with irradiation, as it has a relatively
low rate of distant metastases – less than 20%. Con-
ventionally fractionated radiotherapy alone seems to be an
effective treatment for early stages of the disease (T1-2;
N0-1). In more advanced stages of oroharyngeal cancer
(T3-4 and / or N2-3) the results of radical radiotherapy are
poor. It is expected that about 60% of patients with locally
advanced disease are not cured after radiotherapy, or
have local recurrence. Alternative treatment is surgery,
followed by adjuvant radiation. Combined modality
treatment with surgery is the method of choice in the
United States and in some centers in Western Europe.
However, the rate of loco-regional failure after surgery
and radiotherapy is also high. Surgical procedures are also
problematic because the cosmetic and functional effects of
wide resection and reconstruction are often unsatisfactory.
Currently the majority of patients with locally advanced
oropharyngeal cancer are referred for modern treatment,
such as concomitant radiochemotherapy, or uncon-
ventionally fractionated radiotherapy.
Results of radiotherapy for oropharyngeal cancer
depend on both tumor and patient characteristics, as well
as on several factors connected with the treatment. The
influence of factors which characterize the patient and
the tumor is rather well known, while the predictive and
prognostic value of the othert factors remains unclear,
and even controversial. The importance of the total dose,
dose per fraction, overall treatment time, and the
presence, reasons for and duration of breaks in
radiotherapy have been discussed for a long time.
The aim of this study is to summarize the long-term
results and to estimate the influence of the clinical and
treatment-related factors on radiotherapy outcome in
patients with oropharyngeal cancer.
Material and methods
Between February 1984 and December 1995, 432 patients with
microscopically proven squamous cell carcinoma of the
oropharynx have been registered in the Department of
Radiotherapy of the Maria Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology in Warsaw. 241 patients were
referred for radical radiotherapy. Another 7 patients were
qualified for surgery followed by radiation. 133 patients were
referred for palliative irradiation. 30 patients were suitable for
symptomatic care only due to a poor performance status. The
remaining 21 patients decided to be treated in other centers.
All 241 patients referred for radical radiotherapy were
analysed. The clinical stages of the disease were established
based on the TNM UICC classification from 1987[2].
The analysis was performed basing on the data from
individual registered case reports. Patients who had received
below 50 Gy were excluded from the local control analysis – i.e.
a few patients who discontinued therapy due to medical reasons
or refusal. All patients were included into overall survival
analysis. Between 1984 and 1995 the same medical staff was
engaged in the radiation treatment according to a uniform
therapeutic protocol. Cobalt-60 therapy was applied in 234
(97%) patients. Seven patients were treated with photon beams
of energy range between 4 and 15 MeV.
Immobilization of the head and neck region with orfit or
celon shells and simulator for treatment planning were applied
in all cases. The medical physics team performed the calculations
of dose homogeneity in the irradiated volume. Initially we used
manually prepared outlines. Mevaplan system basing on CT
imaging has been used for treatment planning since 1987. The
primary site and the upper neck lymph nodes were irradiated
with the parallel opposite fields technique. The one-field
technique was used for lower neck, supraclavicular and superior
mediastinal lymph nodes if irradiation of this region was
necessary.
Conventional dose fractionation (1.8-2.0 Gy per fraction
once daily for 5 days a week) was usually used (98% of patients).
The planned total dose was 66-70 Gy. Deviations from protocol
were made in patients who showed a lack of complete regression
after the prescribed dose. In these cases the total dose was
increased. During irradiation of the primary site and of upper
neck nodes, after delivering a dose of 44 Gy the spinal cord was
protected. The dose to the posterior necks lymph nodes was
increased to 50-60 Gy with 9-10 MeV electron. In case of lack of
complete regression of the metastatic lymph nodes after the
prescribed dose the total dose was increased with electrons. The
usual elective dose for lower neck, supraclavicular and upper
mediastinal lymph nodes was 50 Gy.
Patient and tumour characteristics are presented in Table I.
Factors connected with the applied therapy are presented in
Table II. The retrospective character of the analysis limits the
possibilities to investigate the influence of the total doses and
doses per fraction, because the method of dose fractionation
and the total dose do not exceed routinely used radical doses.
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sze ryzyko zgonu u chorych z cechà N2c (p=0.002). Istotnym czynnikiem wp∏ywajàcym niekorzystnie na czas prze˝ycia ca∏-
kowitego, okaza∏ si´ niski poziom hemoglobiny (p=0,0002). Równie˝ chorzy, u których stosowano przerwy w napromienia-
niu, mieli gorsze rokowanie w porównaniu do pozosta∏ych (p=0,06). Jedynym istotnym statystycznie czynnikiem, wp∏ywajà-
cym na czas prze˝ycia bez progresji miejscowej lub regionalnej, w oparciu o wyniki analizy wielowariantowej, okaza∏o si´ st´-
˝enie hemoglobiny (p=0,013).
W n i o s k i.  Czynnikami wp∏ywajàcymi na czas prze˝ycia chorych na raka ustnej cz´Êci gard∏a, poddanych radykalnej radio-
terapii, sà stopieƒ sprawnoÊci, zaawansowanie loko regionalne raka, st´˝enie hemoglobiny oraz przerwy w napromienianiu.
Jedynym czynnikiem wp∏ywajàcym na ryzyko nawrotu loko regionalnego okaza∏o si´ st´˝enie hemoglobiny.
Key words: oropharyngeal cancer, radiotherapy, prognostic factors
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The influence of the overall treatment time on survival and local
control was estimated indirectly by analyzing the length of the
breaks divided in 3 categories: up to 5 days, between 6-10 days
and above 10 days. The reasons for breaks were also analyzed.
The influence of complete regression (with reference to survival
and local control) was estimated up to 4 weeks from the end
of treatment.
S t a t i s t i c a l  m e t h o d s
Parameters characterizing patients were analyzed using standard
statistic tools: mean and standard deviation, median and quartile
and the frequency tables. Curves of overall survival and local
control were estimated using the Kaplan-Meier method. Analysis
of the prognostic factors was performed using Cox's multivariate
proportional risk model. With the use of backward selection
the statistically significant variables were set at p=0.05.
The following factors were included into analysis: WHO
performance status, primary tumor site, pathology, clinical T N
stage, blood count (RBC, Hb, HCT), presence and length of
the breaks during treatment.
The correlation between the WHO performance status
and hemoglobin concentration was investigated using the χ2 test.
Results of the treatment
O v e r a l l  s u r v i v a l  a n a l y s i s
Five year overall survival for all 241 analyzed patients
was 25%. The overall survival curve is presented in
Figure 1. Median survival time was 24 months, 95%
C.I. = (19.7, 29.1). Five year overall survival was 39%
(6 patients) for clinical stage T1, 36% (21 patients) for T2,
25% (23 patients) for T3 and 13% (5 patients) for T4.
Statistical analysis showed that in the case of clinical stage
T4 the risk of death was 2 times higher, as compared to
patients with clinical stage T1 (p=0.04). This correlation
is presented in Table III.
233 patients (8 patients were excluded from this
analysis due to incomplete data) were included in the
multivariate analysis aimed at estimating the influence
of the analyzed factors on the overall survival. Results of
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Table II. Treatment characteristics
N=241
Beam
4 MeV 1 (0.4%)
9 MeV 4 (2%)
10 MeV 1 (0.4%)
15 MeV 1 (0.4%)
Co60 234 (97%)
Dose per fractions
150 1 (0.4%)
160 1 (0.4%)
180 55 (23%)
200 180 (75%)
220 1 (0.4%)
225 1 (0.4%)
300 2 (1%)
Total dose 
(min, max) (700, 7600)
medium (25%, 75%) 6600 (6600, 7000)
Treatment interruptions 138 (57%)
< 5 days 24 (17%)
6 - 10 days 51 (37%)
> 10 days 63 (46%)
Complete remission (CR) at the end of treatment 153 (63%)
CR  4 weeks after end of treatment 175 (73%)
241 118 75 41 21 nb. events mediana
100% 50% 34% 25% 21% 184 24.4 [19.7, 29.1]
Figure 1. Overall survival
Table I. Clinical material 
N=241
Sex
Female 27 (11%)
Male 214 (89%)
Age
(min, max) (35,  86)
median ( std. dev.) 58 (10.5)
WHO
0 88 (37%)
1 130 (54%)
2 22 (9%)
Incomplete data 1
Localisation 
Tonsil 96 (40%)
Soft palate 17 (7%)
Base of the tongue 34 (14%)
Retromolar trigone 10 (4%)
Lateral/posterior wall 10 (4%)
2, 3  subsite 74 (31%)
Histopathology 
Well differentiated 39 (16%)
Moderate differentiated 79 (33%)
Poor differentiated 54 (22%)
Not defined 69 (29%)
T
T1 17 (7%)
T2 72 (30%)
T3 109 (45%)
T4 43 (18%)
N
N0 81 (34%)
N1 60 (25%)
N2 ab 51 (21%)
N2 c 14 (6%)
N3 34 (14%)
this analysis stress the significant influence of the
following factors on survival: WHO performance status,
clinical stage T and N, hemoglobin concentration and
the presence and length of the breaks during treatment.
The results of this analysis are presented in Table III. We
have proven the influence of the WHO performance
status on survival. Patients with WHO performance status
2 had significantly worse prognosis, than patients with
ratio WHO performance status 0 (p=0.02). The influence
of clinical stage T on survival was statistically significant in
patients with stage T4, as compared to those with stage T1
(p=0.04). For clinical stages T2 and T3 no statistical
significance was noticed. Influence of the presence or
lack of metastases to lymph nodes of the neck (N0 versus
N+) was not proven. However, the analysis has shown
the unfavorable influence of clinical stage N2c for
survival. Patients with clinical stage N2c had three-fold
higher risk of death, as compared to all others (p=0.002).
Hemoglobin (Hb) concentration was also found to be
a factor with significant influence on survival. Hb level
above 13g/dL reduced the risk of death by half, as
compared to the patients with Hb level equal or lower
than 13g/dL (p=0.0002). We have also found a correlation
between Hb level lower than 13g/dL and poor per-
formance status (WHO 2) (p=0.034). This correlation is
presented in Table IV.
Patients with breaks during radiation resulting in
prolonged overall treatment time had worse prognosis, as
compared to patients without treatment breaks. This
relationship was marginally significant (p=0.06). Sta-
tistically significant influence on survival was observed
in patients with treatment breaks lasting up to 5 days
(p=0.01). No significant influence on survival was
observed in patients with longer breaks in the treatment.
Other analyzed factors, such as tumor localization within
the oropharyngeal region, cancer differentiation and
blood count parameters other than Hb had no significant
influence on survival.
Overall survival curves, including significant factors
such as the WHO performance status, clinical stages T
and N, breaks in treatment and hemoglobin level are
presented on Figure 2.
L o c a l  c o n t r o l  a n a l y s i s
Survival period without recurrences in the primary site
and necks lymph nodes was defined for patients who had
complete regression (CR) up to 4 weeks after the end of
the irradiation. This is a period between the end of
treatment and the diagnosis of loco-regional recurrence
or the latest follow up visit without symptoms of
recurrence. Patients, who had died within 2 months after
the last follow up visit, when no recurrence was observed
have been assessed according to the date this visit.
The survival curve without loco-regional recurrence
for 175 patients who had CR after the treatment is
presented in Figure 3. The probability of 5-year survival
without loco-regional recurrence was 55%. The pro-
bability of 5-year survival without loco-regional recurrence
was 65% for patients with stage T1 (5 patients), 68%
(16 patients) for stage T2, 51% (17 patients) for stage
T3 and 39% (5 patients) for stage T4. 166 patients
entered the multivariate analysis. Five patients were
withdrawn due to incomplete data and four due to control
time equal to 0. Multivariate analysis showed that only
Hb level had a significant influence on survival without
loco-regional recurrence. In the group of patients
with Hb level above 13g/dL the risk of recurrence was
lower by 40%, as compared to patients with Hb level
equal or lower than 13g/dL (p=0.013). These results are
presented in Table V. Other analyzed factors had no
significant influence on survival without loco-regional
recurrence.
Curves illustrating the influence of the Hb level on
survival without loco-regional recurrence are presented in
Figure 4.
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Table V. Loco - regional control analysis
N=166 RR 95% C.I. dla RR p
HB
> 13 vs ≤ 13 0.62 [0.43, 0.9] 0.013
Table IV. WHO performance status 
and hemoglobin concentration influences
WHO ≤ 13 > 13 p
0 24 (31%) 63 (40%) 0.034
1 41 (53%) 86 (54%)
2 12 (16%) 9 (6%)
Total 77 (100%) 158 (100%)
Table III. Overall survival analysis
N=233 RR 95% C.I. dla RR p
WHO 
2 vs 0 1.9 [1.1, 3.3] 0.02
1 vs 0 0.44
N
N2c vs N0 2.6 [1.4, 5.0] 0.002
N3 vs N0 0.15
N2 ab vs N0 0.97
N1 vs N0 0.74
T
T4 vs T1 2.2 [1.0, 4.7] 0.04
T3 vs T1 0.33
T2 vs T1 0.97
HB
> 13 vs ≤ 13 0.54 [0.40, 0.75] 0.0002
Interruption during the 1.3 [1.0, 1.8] 0.06
treatment yes vs no breaks
Pa t t e r n  o f  f a i l u r e
Failures connected with cancer were observed in 57%
(138 patients). 76% (184 patients) died.
Failures in the primary site (no complete regression
after radiotherapy or recurrences) were observed in 47%
(112 patients). Neck lymph node recurrences were
frequently accompanied by progression in the primary
site and amounted to 23% (56 patients). Distant
metastases occurred in only 6% (14 patients). Second
primary malignancies occurred in 4% (10 patients). These
results are presented in Table VI.
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Figure 2 (1)
Figure 2. Survival curves for different prognostic factors 
Figure 2 (3) Figure 2 (4)
Figure 2 (5)
Figure 2 (2)
Table VI. Treatment failures
Failures 138 (57%)
Local recurrences 112 (47%)
Lymph node metastases 56 (23%)
Distant metastases 14 (6%)
Second malignancy 4 (10%)
Death 184 (76%)
Tr e a t m e n t  t o l e r a n c e
Early toxicity was estimated according to modified Dische
scale. Acute radiation reactions in patients treated before
1990 were re-classified basing on the case record entries.
Numerical and percentage comparison of early reactions
is presented in Table VII. The use of the feeding tube,
justified by heavy dysphagia, was necessary in 21% of
patients. Dry desquamation of epidermis occurred in 81%
patients while the moist reaction in 30%. Despite of the
confluent mucositis in 62% of patients and intensive pain
on swallowing in 29% cases, opioids were used only in
2% of patients.
Late toxicity was estimated during follow up visits
after the termination of treatment and after disappea-
rance of early reaction. Intensive xerostomia was observed
in 6% of patients of the 51% with this symptom. La-
ryngeal oedema was observed in 3% cases. Cartilage
necrosis was not observed. Post-radiation bone necrosis is
one of the most serious side effects after radiotherapy.
Bone necrosis had occurred in 4 cases, which amounts
to 2% of all analyzed patients. Late reactions are
presented in Table VIII.
Table VIII.  Late toxicity
N=241
Xerostomia
No 93 (42%)
Moderate 114 (51%)
Severe 14 (6%)
Missing 20
Larynx oedema
Yes 225 (97%)
No 6 (3%)
Others 1 (0.4%)
Missing 9
Osteonecrosis
No 227 (98%)
Yes 4 (2%)
Missing 10
Discussion
Retrospective analysis refers to patients with squamous
cell carcinoma of the oropharynx qualified and treated
with radical radiotherapy at the Department of Radio-
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175 81 59 30 16 nb. events mediana
100% 62% 55% 55% 55% 68 -
Figure 3. Loco - regional control 
Table VII. Early toxicity
N=241
Pain at swallowing
No 8 (3%)
Moderate 163 (68%)
Severe 69 (29%)
Missing 1
Dysphagia
No 27 (11%)
Moderate 163 (68%)
Severe 49 (21%)
Missing 2
Need for analgesia
General analgesia 222 (98%)
Narcotics 5 (2%)
Missing 14
Erythrema
No 4 (2%)
Moderate 126 (52%)
Severe 111 (46%)
Dry desquamation
Yes 195 (81%)
No 45 (18%)
Missing 1
Moist desquamation
Yes 72 (30%)
No 167 (70%)
Missing 2
Mucositis
No 21 (9%)
Patchy 69 (29%)
Confluent 151 (62%)
Figure 4. Loco - regional control curves depending on haemoglobin
concentration 
therapy of the Maria Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology in Warsaw over a period
of 11 years. The object of this work was not only to
present our results, but also to estimate the prognostic
role and impact of the clinical factors as well as the factors
connected with treatment on the overall survival and
loco-regional control.
Five-year overall survival amounts to 25% and is
similar to results presented by other authors basing on
clinical material with similar loco-regional stages of the
disease [3, 4]. In the presented material 152 patients
(63%) had T3 or T4 stage tumours, and 89 patients (37%)
had N2 or N3 metastatic lesions in the neck lymph nodes.
T stage is a well known clinical factor influencing the
radiotherapy outcome. Some published data has proven
that, when combined with its localization, the primary
site advancement could be the only statistically significant
prognostic factor in patients with oropharyngeal cancer
treated with radiotherapy [3-6]. Five-year survival
presented by different authors ranged from 70 to 90%
in T1 patients, 50 to 60% in T2 patients, 30 to 50% in T3
patients and from 10 to 25% in T4 patients [5]. In the
presented analysis we observed a significant influence of
the T stage on overall survival. These results agree with
data of other authors.
Looking at the survival curves (Figure 2) one can
notice that curves for T1 and T2 almost overlap. The
course of the T3 curve correlates with a lower survival
ratio, but statistical significance was not proven for this
stage. Friesland [4] presents similar statistical
insignificance between survival in patients with T2 and
T3. He explains it with the high percentage of metastases
in cervical lymph nodes in T2 with N3 supremacy. It
seems that the presence of N2abc and N3 in 37% cases in
our material explains the obtained results.
The presence and magnitude of metastases in the
neck lymph nodes is an important factor with influence on
the overall survival in patients with oropharyngeal cancer
[6, 7].
Although the percentage of 5-year overall survivals
shows the influence on the presence of metastases in
lymph nodes (N0 versus N+), no statistical significance
was found in these groups. In the analysis of separate
categories (N0, N1, N2abc, N2c and N3) statistically
significant difference was observed for group N2c. It
correlated with a three-fold risk of death while other
categories were not statistically significant.
Lack of the significant influence of stage N+ on
survival was also observed in other published data, while
the unclear selective significance of worse prognosis of
N2c patients is not more surprising than worse results in
N0 versus N1 patients obtained by other authors [4].
According to the present opinion overall treatment
time with the constant total dose has influence on local
and regional recovery, thus resulting in survival.
Prolongation of the treatment time is connected with
worse prognosis [8-12]. Only Bataini's study [6] presents
different results. It was also confirmed by own earlier
experiences [13]. In the presented analysis we observed
the influence of the prolongation of overall treatment
time on survival by analyzing the influence treatment
breaks in 3 categories: up to 5 days, 6-10 days and over 10
days. The highest ratio of 5-year survival was observed
in patients without treatment breaks. The increase of the
risk of death was found in patients with breaks, as
compared to patients without breaks. The influence of
breaks above 5 days was not statistically significant while
breaks up to 5 days influenced worse prognosis.
Radio-resistance arising from hypoxia, is still
a controversial issue to be discussed. The influence of
Hb concentration – the factor responsible for oxygenation
of tissues – on local recovery was proven by other authors
[14]. In the presented analysis Hb over 13 g/dL had
significant influence on treatment results (overall survival)
and, as the only statistically significant factor, on loco-
regional control.
Performance status is a patient-dependant prognostic
factor. Many papers show that poor performance status is
connected with worse response to treatment [13, 15].
Analysis of our data has proven the influence of worse
performance status on survival. WHO-2 was connected
with 2 times higher risk of death, as compared with WHO
0-1. We have also shown a correlation between worse
performance status and lower Hb level. The connection
between Hb concentration and the performance status
has been suggested by other authors [13, 15].
Other clinical factors and factors connected with the
treatment did not influence overall survival and local
control.
Oropharyngeal cancer belongs to a group of
malignancies in which patient and tumor characteristics
may dominate over treatment-related factors [16].
According to some authors the T and N stages are the
only significant prognostic factors which influence survival
[3-6]. Improvement in radiotherapy outcomes may result
from the administration of significantly higher doses while
minimizing the risk of late reactions – after the
application of a few fractions per day [17-19], using
accelerated fractionation schedules as well as new
possibilities of scheduled therapy. 3D planning allows for
a precise definition of the irradiated volume and for the
maximum protection of critical organs.
Summary
Oropharyngeal cancer in the initial T stage is hardly
recognizable. We have proved that at the moment of
classification we usually deal with locally advanced tumor
T3, T4, N2abc, N3, which influences treatment results.
Moreover, 1/5 of patients with stage T2 had metastases in
lymph nodes (N2abc, N3). It explains the lack of
differences in the survival curve for T2 and T3.
In the analysis of overall survival a constant decrease
of the survival ratio is observed. When comparing survival
without loco-regional recurrence with overall survival we
can state that local and regional recurrence occurs up to 2
years after treatment, while later the risk of occurrence is
close to nill.
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The decrease of the survival ratio 3 years after
treatment termination should be explained in detail, since
the death of patients is connected with generalization of
the disease – distant metastases were observed in 6% of
patients and second primary carcinoma was observed in
4% of patients. These patients have died for other
reasons, which should be identified and the role and
significance of which should be estimated.
Hemoglobin level turned out to be an important
factor, which influences the possibility of local and
regional recovery as well as overall survival and survival
without symptoms. Clinical observations and the results of
the analysis have proved the correlation between Hb level
and patients' WHO performance status. Both factors
influence treatment results, while a lower Hb level
accompanied by worse performance status defines the
group of patients with worse prognosis.
Zbigniew Szutkowski MD, PhD
Department of Head and Neck Cancer
The Maria Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology
Roentgena 5 str. 02-781 Warsaw, Poland
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